BioSpace News Archive

On the heel of the regulatory meeting with Health Canada on March 31st 2023, CELL Technologies Inc. announces the submission of the clinical data of its stem cell program in pain for Health Canada approval.

Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago.

Contraline, Inc., a clinical-stage medical device company announced the acceptance of abstracts detailing the initial results from the company’s first in human clinical trial of ADAM, a hydrogel-based, long-lasting, non-hormonal, and non-permanent male contraceptive.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of uliledlimab, the Company’s proprietary and highly differentiated CD73 antibody, in combination with PD-1 therapy in non-small-cell lung cancer (NSCLC), will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

InDex Pharmaceuticals Holding AB invites investors, analysts and media to attend a live business update during which Jenny Sundqvist, CEO, and the InDex Pharmaceuticals leadership team will share insights and updates on the company’s mission to improve the lives of patients suffering from immunological diseases.

Royal Philips, a global leader in health technology, announced that the company earned a spot on Forbes’ 2023 “America’s Best Employers for Diversity” list.

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis.

CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission on April 26, 2023.

Theseus Pharmaceuticals, Inc. today announced that initial dose escalation data from the ongoing phase 1/2 study of THE-630 in advanced gastrointestinal stromal tumors (GIST) were accepted for online publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.

Bicara Therapeutics today announced that it will present dose expansion data from the ongoing Phase 1/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.